Novo Sees U.S. Price Gains Even With New Sanofi Insulin
This article is for subscribers only.
Novo Nordisk A/S is confident it will be able to raise prices in the U.S. on its diabetes products this year and next, even with increasing competition from Sanofi and copycat developers.
The Danish company expects net price increases of a “low single-digit” percentage, after rebates, on its insulin and other diabetes products, Chief Operating Officer Kaare Schultz said yesterday in an interview in London. Schultz, 53, was given the additional title of president last year, fueling speculation that he may become Novo’s next chief executive officer.